Effects of interleukin-13 and montelukast on the expression of zonula occludens-1 in human podocytes

Se Jin Park, Moin A Saleem, Ja-Ae Nam, Tae-Sun Ha, Jae Il Shin

Research output: Contribution to journalArticle (Academic Journal)peer-review

10 Citations (Scopus)


PURPOSE: The aim of this study was to investigate whether pathologic changes in zonula occludens-1 (ZO-1) are induced by interleukin-13 (IL-13) in the experimental minimal-change nephrotic syndrome (MCNS) model and to determine whether montelukast, a leukotriene receptor antagonist, has an effect on ZO-1 restoration in cultured human podocytes.

MATERIALS AND METHODS: Human podocytes cultured on bovine serum albumin-coated plates were treated with different doses of IL-13 and montelukast and then examined for distribution using confocal microscopy and for ZO-1 protein levels using Western blotting.

RESULTS: ZO-1 was internalized and shown to accumulate in the cytoplasm of human podocytes in an IL-13 dose-dependent manner. High doses (50 and 100 ng/mL) of IL-13 decreased the levels of ZO-1 protein at 12 and 24 h (both p<0.01; n=3), which were significantly reversed by a high dose (0.5 μM) montelukast treatment (p<0.01; n=3).

CONCLUSION: Our results suggest that IL-13 alters the expression of ZO-1, and such alterations in the content and distribution of ZO-1 may be relevant in the pathogenesis of proteinuria in the MCNS model.

Original languageEnglish
Pages (from-to)426-32
Number of pages7
JournalYonsei Medical Journal
Issue number2
Publication statusPublished - Mar 2015


  • Acetates
  • Blotting, Western
  • Dose-Response Relationship, Drug
  • Humans
  • Interleukin-13
  • Leukotriene Antagonists
  • Microscopy, Confocal
  • Podocytes
  • Proteinuria
  • Quinolines
  • Tight Junctions
  • Zonula Occludens-1 Protein


Dive into the research topics of 'Effects of interleukin-13 and montelukast on the expression of zonula occludens-1 in human podocytes'. Together they form a unique fingerprint.

Cite this